TrovaGene (TROV) announced that it had achieved positive preclinical findings using its drug onvansertib in combination with AbbVie's (ABBV) Venclexta (Venetoclax). This is in the early stage of testing, but it could provide a very good alternative for these patients, in that they won't be bombarded with chemotherapy type of treatments. This piece of news builds upon the release of positive results observed using onvansertib in combination with chemotherapy drugs several weeks ago. It seems that onvansertib is highly versatile and it is likely that it could be adapted into several